Physiology
Neuromuscular Junction
The synapse where motor neurons command skeletal muscle to contract
The neuromuscular junction (NMJ) is the specialized synapse between an alpha motor neuron and a skeletal muscle fiber. Action potential arrives at the presynaptic terminal; voltage-gated calcium channels (Cav2.1, P/Q-type) open; Ca²⁺ triggers fusion of synaptic vesicles (~1000 per terminal, each containing ~10,000 ACh molecules) with the active zone; acetylcholine is released into the ~50 nm cleft; binds nicotinic ACh receptors on the motor end plate (with junctional folds amplifying surface area); cation flux generates the end-plate potential, which triggers a muscle action potential and contraction. Acetylcholinesterase in the cleft hydrolyzes ACh within ~1 ms, terminating the signal. Pathology — myasthenia gravis (anti-AChR antibodies), Lambert-Eaton (anti-Cav2.1), botulism (toxin cleaves SNAREs), organophosphate poisoning (AChE inhibition) — illustrates each step. NMJ blockers are essential for surgical anesthesia.
- Synaptic cleft width~50 nm
- ACh per vesicle (quantum)~10,000 molecules
- Vesicles released per AP~100-200 (large safety factor)
- ACh hydrolysis<1 ms by acetylcholinesterase
- Receptor typeNicotinic (cation-permeable ligand-gated channel)
- Synaptic delay~0.5-1 ms
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why the NMJ matters
- Voluntary movement. Every skeletal muscle action passes through this synapse.
- Anesthesia. Paralysis for intubation and surgery uses NMJ blockers.
- Myasthenia gravis. Autoimmune NMJ disease.
- Botulism and tetanus. Toxins target presynaptic machinery.
- Organophosphate poisoning. AChE inhibition; pesticides, nerve agents.
- Therapeutic Botox. Cosmetic, dystonia, spasticity, migraine, hyperhidrosis.
- EMG diagnostics. Repetitive nerve stimulation distinguishes pre- vs post-synaptic disease.
Common misconceptions
- NMJ uses many neurotransmitters. Only ACh; nicotinic receptors only.
- One AChR opens per ACh molecule. Two ACh needed per receptor.
- MG and LEMS look identical. MG worsens with use; LEMS improves.
- Sugammadex reverses everything. Only steroidal NMBs (rocuronium, vecuronium); not succinylcholine or atracurium.
- Botox works on muscle directly. Cleaves presynaptic SNAREs, blocking ACh release.
- Synaptic transmission is instantaneous. ~0.5-1 ms delay — mostly the time for vesicle fusion.
Frequently asked questions
How does ACh release happen?
Action potential depolarizes the motor terminal. Voltage-gated Cav2.1 (P/Q-type) calcium channels open. Local Ca²⁺ rises from ~100 nM to ~100 μM at active zones. Ca²⁺ binds synaptotagmin on synaptic vesicles. SNARE proteins (synaptobrevin/VAMP on vesicle, syntaxin and SNAP-25 on membrane) zipper, fusing vesicle with terminal membrane. ~100-200 vesicles release per AP at the NMJ — a "safety factor" of ~3-5× the threshold needed for muscle activation, ensuring reliable transmission.
How does the postsynaptic side respond?
ACh diffuses across cleft and binds nicotinic AChR (pentameric: 2α, β, δ, ε in adult; γ in fetal — embryonic isoform). Two ACh molecules required per receptor for opening. Channel opens for ~1 ms; Na⁺ in, K⁺ out (small Ca²⁺); local depolarization = end-plate potential (EPP), normally ~30-40 mV. EPP exceeds threshold → opens nearby voltage-gated Na⁺ channels → muscle action potential propagates along sarcolemma and into T-tubules, triggering Ca²⁺ release and contraction. Junctional folds concentrate Na⁺ channels at depths to amplify EPP-to-AP conversion.
How is the signal terminated?
Acetylcholinesterase (AChE) in the basal lamina of the synaptic cleft hydrolyzes ACh into choline and acetate within <1 ms. Choline is recycled — taken back by sodium-dependent transporters into the terminal, used to synthesize new ACh by choline acetyltransferase (ChAT). One AChE molecule cleaves ~5,000 ACh/sec — extraordinarily fast. AChE inhibition (organophosphates, nerve agents) causes ACh accumulation, persistent depolarization, paralysis, and cholinergic crisis (SLUDGE — salivation, lacrimation, urination, defecation, GI upset, emesis).
What is myasthenia gravis?
Autoimmune disease — IgG antibodies against postsynaptic nicotinic AChR (~85%) or MuSK (~10%) reduce functional receptor density. Fewer receptors → smaller EPP → some EPPs fail to reach threshold → fluctuating, fatigable weakness (improves with rest, worsens with use). Classically: ptosis, diplopia, bulbar symptoms (dysarthria, dysphagia), proximal weakness; can progress to respiratory failure (myasthenic crisis). Diagnosis: anti-AChR antibody titer, repetitive nerve stimulation showing decremental response, single-fiber EMG, ice pack test for ptosis. Treatment: pyridostigmine (AChE inhibitor), thymectomy, immunosuppression (steroids, azathioprine, MMF), IVIG/plasmapheresis acutely, eculizumab/efgartigimod for refractory.
What about Lambert-Eaton and botulism?
LEMS — autoantibodies to presynaptic Cav2.1 reduce calcium entry, decreasing ACh release. Proximal weakness improves with sustained effort (incremental on EMG — opposite of MG). ~50% paraneoplastic with small cell lung cancer. Treatment: amifampridine (3,4-DAP) blocks K⁺ channels, prolonging depolarization. Botulism — botulinum toxin (Clostridium botulinum) cleaves SNARE proteins (SNAP-25, syntaxin, VAMP), preventing vesicle fusion. Descending paralysis. Treatment: equine antitoxin, supportive (ventilation). Therapeutically used (Botox) for cosmetic, dystonia, spasticity, hyperhidrosis, chronic migraine.
How do neuromuscular blockers work in anesthesia?
Two classes. Depolarizing — succinylcholine binds AChR and persistently depolarizes (lasts ~5 min); muscle initially fasciculates then becomes flaccid; hydrolyzed by plasma butyrylcholinesterase (pseudocholinesterase deficiency = prolonged paralysis); risk of malignant hyperthermia, hyperkalemia in burns/denervation. Non-depolarizing — competitive antagonists (rocuronium, vecuronium, atracurium, cisatracurium) lasting 30-60 min; reversed by neostigmine + glycopyrrolate (raises ACh) or sugammadex (binds rocuronium directly — fast, complete). Used to facilitate intubation and surgery.
What's the difference between CNS synapses and the NMJ?
NMJ uses ACh and nicotinic receptors only; one input per fiber; very high safety factor; reliable 1:1 transmission. CNS synapses are diverse (glutamate, GABA, glycine, monoamines, neuropeptides; many receptor subtypes including ionotropic and metabotropic); each neuron receives thousands of inputs; transmission probabilistic (release probability often 10-50%); plasticity (LTP, LTD) underlies learning. NMJ is essentially "always on" when commanded — failure is pathological. CNS synapses integrate, modulate, and learn.